Skip to main content
PMC home page
American Journal of Human Genetics logoLink to American Journal of Human Genetics
. 1984 Sep;36(5):1024–1038.

Beta-thalassemia disease prevention: genetic medicine applied.

C R Scriver, M Bardanis, L Cartier, C L Clow, G A Lancaster, J T Ostrowsky
PMCID: PMC1684522  PMID: 6496471

Abstract

We report here an evaluation of a program for thalassemia-disease prevention, comprising education, population screening for heterozygotes, and reproductive counseling; the evaluation includes cost analysis. A preprogram survey in 1978 of 3,247 citizens in the high-risk communities (85% were high-school students) showed that 88% favored a program but that only 31% considered fetal diagnosis as an acceptable option. Screening in high school or before marriage was preferred by 56%. In a 25-month period (December 1979-December 1982), we screened 6,748 persons, including 5,117 senior high-school students, using MCV/HbA2 indices. The participation rate was 80% in the high-school group. The frequency for beta-thalassemia heterozygosity was 4.7% with 10-fold variation among ethnic groups at risk; the overall frequency for all variants found was 5.4%. We surveyed 60 carriers and 120 noncarriers after screening high-school students (response rate 77%): most carriers told parents (95%) and friends (67%) the test result; and 38% of the carriers' parents (vs. 18% of the noncarriers' parents) were also screened. Carriers would ascertain their spouses' genotype (91%) and approved uniformly (95%) the high-school screening experience and its goal. We performed 11 fetal diagnoses in a 25-month interval (greater than 75% participation in target population) either by fetoscopy and globin-chain analysis or by amniocentesis and genomic DNA analysis; two of three affected fetuses were aborted at parental request, there was one spontaneous abortion (after fetoscopy), and seven live births. The at-risk couples claimed pregnancy would not be contemplated without the fetal-diagnosis option. We analyzed economic costs of the program: cost per case prevented is approximately equal to $ 6,700, slightly less than cost-per-patient-treatment-year or about 4% of undiscounted treatment cost incurred in the first 25 years of life for an affected individual. These findings indicate: collective acceptance of the program, appropriate attitudes among carriers, general acceptance and efficacy of fetal diagnosis, and global cost-effectiveness.

Full text

PDF
1038

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Angastiniotis M. A., Hadjiminas M. G. Prevention of thalassaemia in Cyprus. Lancet. 1981 Feb 14;1(8216):369–371. doi: 10.1016/s0140-6736(81)91682-2. [DOI] [PubMed] [Google Scholar]
  2. Barrai I., Vullo C. Assessment of prospective genetic counseling in the Ferrara area. Am J Med Genet. 1980;6(3):195–204. doi: 10.1002/ajmg.1320060304. [DOI] [PubMed] [Google Scholar]
  3. Barrai I., Vullo C. Screening for beta-thalassaemia heterozygotes. Lancet. 1980 Dec 6;2(8206):1257–1257. doi: 10.1016/s0140-6736(80)92529-5. [DOI] [PubMed] [Google Scholar]
  4. Beck E., Blaichman S., Scriver C. R., Clow C. L. Advocacy and compliance in genetic screening. Behavior of physicians and clients in a voluntary program of testing for the Tay-Sachs gene. N Engl J Med. 1974 Nov 28;291(22):1166–1170. doi: 10.1056/NEJM197411282912206. [DOI] [PubMed] [Google Scholar]
  5. Boehm C. D., Antonarakis S. E., Phillips J. A., 3rd, Stetten G., Kazazian H. H., Jr Prenatal diagnosis using DNA polymorphisms. Report on 95 pregnancies at risk for sickle-cell disease or beta-thalassemia. N Engl J Med. 1983 May 5;308(18):1054–1058. doi: 10.1056/NEJM198305053081803. [DOI] [PubMed] [Google Scholar]
  6. Clow C. L., Scriver C. R. Knowledge about and attitudes toward genetic screening among high-school students: the Tay-Sachs experience. Pediatrics. 1977 Jan;59(1):86–90. [PubMed] [Google Scholar]
  7. Congote L. F. Rapid procedure for globin chain analysis in blood samples of normal and beta-thalassemic fetuses. Blood. 1981 Feb;57(2):353–360. [PubMed] [Google Scholar]
  8. Desjardins L., Rousseau C., Duplain J. M., Valet J. P., Auger P. La thalassémie chez les Québécois francophones. Can Med Assoc J. 1978 Oct 7;119(7):709–713. [PMC free article] [PubMed] [Google Scholar]
  9. Holtzman N. A. Genetic screening: for better or for worse. Pediatrics. 1977 Jan;59(1):131–133. [PubMed] [Google Scholar]
  10. Mannucci P. M. Haemophilia care in developing countries. Lancet. 1980 Nov 29;2(8205):1189–1190. doi: 10.1016/s0140-6736(80)92616-1. [DOI] [PubMed] [Google Scholar]
  11. Modell B., Ward R. H., Fairweather D. V. Effect of introducing antenatal diagnosis on reproductive behaviour of families at risk for thalassaemia major. Br Med J. 1980 Jun 7;280(6228):1347–1350. doi: 10.1136/bmj.280.6228.1347. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Motulsky A. G. Screening for sickle cell hemoglobinopathy and thalassemia. Isr J Med Sci. 1973 Sep-Oct;9(9):1341–1349. [PubMed] [Google Scholar]
  13. Mouzouras M., Camba L., Ioannou P., Modell B., Constantinides P., Gale R. Thalassaemia as a model of recessive genetic disease in the community. Lancet. 1980 Sep 13;2(8194):574–578. doi: 10.1016/s0140-6736(80)92003-6. [DOI] [PubMed] [Google Scholar]
  14. Rowley P. T., Fisher L., Lipkin M., Jr Incorporation of screening and genetic counseling for beta-thalassemia trait into primary health care: effects on knowledge and attitudes. Birth Defects Orig Artic Ser. 1982;18(7):231–241. [PubMed] [Google Scholar]
  15. Rowley P. T., Fisher L., Lipkin M., Jr Screening and genetic counseling for beta-thalassemia trait in a population unselected for interest: effects on knowledge and mood. Am J Hum Genet. 1979 Nov;31(6):718–730. [PMC free article] [PubMed] [Google Scholar]
  16. Screening for thalassaemia. Lancet. 1980 Nov 29;2(8205):1188–1189. [PubMed] [Google Scholar]
  17. Scriver C. R., Laberge C., Clow C. L., Fraser F. C. Genetics and Medicine: an evolving relationship. Science. 1978 May 26;200(4344):946–952. doi: 10.1126/science.644337. [DOI] [PubMed] [Google Scholar]
  18. Silvestroni E., Bianco I., Graziani B., Carboni C., Valente M., Lerone M., D'Arca S. U. Screening of thalassaemia carriers in intermediate school of Latium: results of four years' work. J Med Genet. 1980 Jun;17(3):161–164. doi: 10.1136/jmg.17.3.161. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Spritz R. A., Forget B. G. The thalassemias: molecular mechanisms of human genetic disease. Am J Hum Genet. 1983 May;35(3):333–361. [PMC free article] [PubMed] [Google Scholar]
  20. Tammis-Hadjopoulos M., Gold R. J., Maag U. R., Metrakos J. D., Scriver C. R. Improved detection of beta-thalassaemia carriers by a two-test method. Hum Genet. 1977 Oct 14;38(3):315–324. doi: 10.1007/BF00402158. [DOI] [PubMed] [Google Scholar]
  21. Williams A. The cost-benefit approach. Br Med Bull. 1974 Sep;30(3):252–256. doi: 10.1093/oxfordjournals.bmb.a071211. [DOI] [PubMed] [Google Scholar]

Articles from American Journal of Human Genetics are provided here courtesy of American Society of Human Genetics

RESOURCES